NCT06106113 is a Phase 1 clinical trial of GST-HG171 Tablets in COVID-19 Pneumonia, sponsored by Fujian Akeylink Biotechnology Co., Ltd..

Who is sponsoring NCT06106113?

NCT06106113 is sponsored by Fujian Akeylink Biotechnology Co., Ltd..

What drugs are being tested in NCT06106113?

Interventions in NCT06106113: GST-HG171 Tablets.

What condition does NCT06106113 study?

NCT06106113 studies COVID-19 Pneumonia.

Is NCT06106113 still recruiting?

NCT06106113 is currently completed. Last updated 30 October 2023.

Last reviewed 2023-10-30 · How we verify

NCT06106113

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function

Completed Phase 1 Last updated 30 October 2023

What this trial tests

Phase 1 trial testing GST-HG171 Tablets in COVID-19 Pneumonia in 24 participants. Completed in 30 May 2023.

Timeline

15 December 2022

Primary endpoint
6 February 2023

30 May 2023

Quick facts

Lead sponsor	Fujian Akeylink Biotechnology Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	15 December 2022
Primary completion	6 February 2023
Estimated completion	30 May 2023
Sites	1 location across China

Drugs / interventions tested

GST-HG171 Tablets — full drug profile →

Conditions studied

COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →

Sponsor

Fujian Akeylink Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired liver function.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.
Zagórska A, Czopek A, Fryc M, Jończyk J. · · 2024 · cited 19× · PMID 39062511 · DOI 10.3390/biom14070797
Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function.
Zhou J, Zhang H, Chen H, Zhang G, et al · · 2024 · cited 4× · PMID 38990016 · DOI 10.1128/aac.00539-24

Verify or expand the search:

Other trials of GST-HG171 Tablets

Trials testing the same drug.

NCT06106126 — Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function · NA · unknown

Other recruiting trials for COVID-19 Pneumonia

Currently open trials in the same condition.

NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting
NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting

Other Fujian Akeylink Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT07090759 — To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) · Phase 3 · recruiting
NCT06263959 — A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 · Phase 2 · recruiting
NCT06087055 — Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants · Phase 1 · completed
NCT06084507 — Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants · Phase 1 · unknown
NCT06106126 — Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06106113 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Akeylink Biotechnology Co., Ltd.
Last refreshed: 30 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06106113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing